Drug
Senaparib clinical trials
Also written IMP4297.
- studies test it
- 14
- open now
- 2
- in phase 3
- 0
- first study started
- 2017
Keep track of what changes. Save the senaparib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
14 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2017 | 2 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 3 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 11
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 3
Impact Therapeutics, Inc. (11) · Fudan University (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Shanghai Junshi Bioscience Co., Ltd. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses senaparib is read from its arms, and is right about nine times in ten.
Testing it · 14
- Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian CancerRecruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06617923Written as Senaparib
- Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein MarkerNot yet recruitingPhase 2Fudan UniversityNCT07120451Written as Senaparib
- Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian CancerCompletedPhase 2Impact Therapeutics, Inc.NCT04089189Written as IMP4297
- An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fasting ConditionCompletedPhase 1Impact Therapeutics, Inc.NCT05390944Written as IMP4297(20mg)
- An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fed ConditionCompletedPhase 1Impact Therapeutics, Inc.NCT05391048Written as IMP4297(20mg)
- A Bioequivalence Study to Compare Senaparib Manufactured at 2 Sites in Healthy Subjects in Fasting StateCompletedPhase 1Impact Therapeutics, Inc.NCT07030439Written as Senaparib 10 mg strength capsules manufactured by WuXi STA (Wuxi) Co., Ltd.
- An Bioequivalence Study to Compare 10mg & 20mg of Senaparib Capsules in Healthy Chinese Subjects Under Fasting ConditionCompletedPhase 1Impact Therapeutics, Inc.NCT07019194Written as Senaparib capsules(20mg)
- IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung CancerCompletedPhase 1/2Impact Therapeutics, Inc.NCT04434482Written as IMP4297(senaparib)
- JS001+IMP4297 in Patients With Advanced CancerWithdrawnPhase 1Shanghai Junshi Bioscience Co., Ltd.NCT05262842Written as JS001+IMP4297
- BA Study of IMP4297 (20mg vs 10mg) in Healthy Male SubjectsCompletedPhase 1Impact Therapeutics, Inc.NCT04351165Written as IMP4297
- IMP4297 DDI (Drug-Drug Interaction)Trial in Healthy Male VolunteersCompletedPhase 1Impact Therapeutics, Inc.NCT04584515Written as IMP4297 40 mg
- The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid TumorsCompletedPhase 1Impact Therapeutics, Inc.NCT03507543Written as IMP4297
- A Study of IMP4297 in Patients With Advanced Solid TumorsCompletedPhase 1Impact Therapeutics, Inc.NCT03508011Written as IMP4297
- IMP4297 Food Effect Trial in Healthy VolunteersCompletedPhase 1Impact Therapeutics, Inc.NCT04057729Written as IMP4297
Codes
What other systems call senaparib · ClinicalTrials.gg INT002064
- MeSH (NLM) C000729920senaparibOne source ClinicalTrials.gov
- UNII (FDA) MNZ4OP95CFSENAPARIBOne source FDA
- NCI Thesaurus C168601SenaparibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000729920 | senaparib | One source ClinicalTrials.gov |
| UNII (FDA) | MNZ4OP95CF | SENAPARIB | One source FDA |
| NCI Thesaurus | C168601 | Senaparib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.